News
MBIO
5.55
-11.34%
-0.71
--B. Riley Adjusts Mustang Bio's Price Target to $10 From $4 After Model Updates, Reverse Stock Split; Keeps Buy Rating
--B. Riley Adjusts Mustang Bio's Price Target to $10 From $4 After Model Updates, Reverse Stock Split; Keeps Buy Rating
MT Newswires · 5d ago
Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade
NASDAQ · 05/26 13:55
B.Riley Financial Remains a Buy on Mustang Bio (MBIO)
TipRanks · 05/26 13:25
SNDL, Invitae among additions to Russell microcap; Inovio, Bionano among deletions
Seeking Alpha · 05/24 17:33
Analysts Are Bullish on These Healthcare Stocks: Poseida Therapeutics (PSTX), Mustang Bio (MBIO)
TipRanks · 05/23 10:20
Mustang Bio: Current report
Press release · 05/22 12:04
Mustang to sell Worcester site for up to $11M, abandons some CAR T cell programs
Seeking Alpha · 05/18 13:48
BRIEF-Mustang Bio Announces Strategic Manufacturing Partnership And Portfolio Updates
Reuters · 05/18 12:10
uBriGene Biosciences To Acquire Mustang Bio's Worcester Manufacturing Facility For Up To $11M And Enters Into A Strategic Manufacturing Partnership To Support Mb-106 And Future Pipeline
Benzinga · 05/18 12:09
Mustang Bio to Sell Massachusetts Manufacturing Facility to uBriGene for $11 Million
Mustang Bio to Sell Massachusetts Manufacturing Facility to uBriGene for $11 Million
MT Newswires · 05/18 09:39
HC Wainwright & Co. Reiterates Mustang Bio (MBIO) Buy Recommendation
NASDAQ · 05/16 05:14
HC Wainwright & Co. Reiterates Buy on Mustang Bio, Maintains $7 Price Target
Benzinga · 05/15 10:57
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Mustang Bio (MBIO) and Cidara Therapeutics (CDTX)
TipRanks · 05/15 10:30
Mustang Bio: Q1 Earnings Insights
Benzinga · 05/12 21:15
Mustang Bio GAAP EPS of -$2.06 beats by $0.95
Seeking Alpha · 05/12 20:16
Mustang Bio Q1 EPS $(2.06) Beats $(3.01) Estimate
Benzinga · 05/12 20:11
BRIEF-Mustang Bio Terminates Loan & Security Agreement By Payment Of $30.7 Million
Reuters · 04/13 11:16
MBIO, ELOX and WINT among mid-day movers
Seeking Alpha · 04/05 17:14
Acuity Brands, C3.ai And Other Big Stocks Moving Lower On Tuesday
Benzinga · 04/04 14:57
Mustang Bio Announced 1:15 Reverse Stock Split
Benzinga · 04/03 16:27
More
Webull provides a variety of real-time MBIO stock news. You can receive the latest news about Mustang Bio through multiple platforms. This information may help you make smarter investment decisions.
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The Company’s pipeline is focused on three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The Company is developing CAR T therapies for hematologic malignancies in partnership with the City of Hope National Medical Center (COH) targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutchinson Cancer Center (Fred Hutch) targeting CD20 (MB-106). It is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103), and PSCA (MB-105).